-- 加拿大皇家银行资本市场（RBC Capital Markets）周四发布的研究报告指出，尽管雅培公司（ABT）在第一财季面临挑战且业绩喜忧参半，并下调了2026年有机营收预期，但其终端市场依然保持健康。 分析师在报告中写道，该公司第一财季面临诸多不利因素，包括呼吸系统疾病市场疲软、持续血糖监测业务表现不佳、美国结构性心脏病业务发展趋势艰难以及营养品业务受阻。 该券商预计雅培2026年每股收益为5.48美元，营收为505.4亿美元。 报告指出，受营养品业务复苏迹象显现、电生理业务增长、核心实验室诊断业务改善、成熟药品业务强劲表现以及Exact Sciences整合至癌症诊断业务等因素的推动，雅培有望在下半年加速增长。 该券商重申了对雅培股票的“跑赢大盘”评级，并将目标价从135美元下调至130美元。
Price: $96.67, Change: $+1.20, Percent Change: +1.26%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.